Date: 2018-09-06
Type of information: Product launch
Product name:
Compound:
Therapeutic area:
Action mechanism:
Company: Virtrial (USA - AZ)
Disease:
Latest news:
- • On September 6, 2018, Virtrial announced the launch of a new telemedicine virtual trial platform. This platform affords pharmaceutical sponsors and CROs an opportunity to create and conduct clinical trials utilizing virtual visits. The advanced technology offers multiple modalities to engage patients and can be used on any device by any clinical trial site. Virtrial’s model will incorporate a hybrid of in-person and virtual video visits that will alleviate some of the key pain points with clinical trials and enable patients to remain more actively engaged in the study. The Virtrial communication platform will automatically manage patient communication and touchpoints and provide a reporting platform for compliance.
- The company is using a virtual care platform to transform telehealth in the clinical research industry. Virtrial offers a patient management program that combines video, text, and email for clinical trial sites to easily, efficiently, and conveniently address specific patient and/or study needs. The platform can be used on any device and at any site. The vision is to replace 25%-50% of standard clinical trial visits with virtual visits to create hybrid studies. This model will be best suited for Phase III and IV studies.
- Mark Hanley, President and CEO at Virtrial, stated, “By utilizing a hybrid model approach to trials, we can enhance current trials by replacing a quarter to half of the visits with virtual video visits. We don’t plan to completely replace in-clinic visits, just maximize available resources to get results in an accurate, compliant, and timely manner.”
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE:
OTC status:
Other news:
Is general: Yes
